ABO blood type association with SARS-CoV-2 infection mortality : A single-center population in New York City
© 2021 AABB..
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a variable clinical course with significant mortality. Early reports suggested higher rates of SARS-CoV-2 infection in patients with type A blood and enrichment of type A individuals among COVID-19 mortalities.
STUDY DESIGN AND METHODS: The study includes all patients hospitalized or with an emergency department (ED) visit who were tested for SARS-CoV-2 between March 10, 2020 and June 8, 2020 and had a positive test result by nucleic acid test (NAT) performed on a nasopharyngeal swab specimen. A total of 4968 patients met the study inclusion criteria, with a subsequent 23.1% (n = 1146/4968) all-cause mortality rate in the study cohort. To estimate overall risk by ABO type and account for the competing risks of in-hospital mortality and discharge, we calculated the cumulative incidence function (CIF) for each event. Cause-specific hazard ratios (csHRs) for in-hospital mortality and discharge were analyzed using multivariable Cox proportional hazards models.
RESULTS: Type A blood was associated with the increased cause-specific hazard of death among COVID-19 patients compared to type O (HR = 1.17, 1.02-1.33, p = .02) and type B (HR = 1.32,1.10-1.58, p = .003).
CONCLUSIONS: Our study shows that ABO histo-blood group type is associated with the risk of in-hospital death in COVID-19 patients, warranting additional inquiry. Elucidating the mechanism behind this association may reveal insights into the susceptibility and/or immunity to SARS-CoV-2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Transfusion - 61(2021), 4 vom: 20. Apr., Seite 1064-1070 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Szymanski, James [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ABO |
|---|
| Anmerkungen: |
Date Completed 19.04.2021 Date Revised 31.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/trf.16339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322232384 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322232384 | ||
| 003 | DE-627 | ||
| 005 | 20231225181612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/trf.16339 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322232384 | ||
| 035 | |a (NLM)33665881 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Szymanski, James |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ABO blood type association with SARS-CoV-2 infection mortality |b A single-center population in New York City |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2021 | ||
| 500 | |a Date Revised 31.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 AABB. | ||
| 520 | |a BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a variable clinical course with significant mortality. Early reports suggested higher rates of SARS-CoV-2 infection in patients with type A blood and enrichment of type A individuals among COVID-19 mortalities | ||
| 520 | |a STUDY DESIGN AND METHODS: The study includes all patients hospitalized or with an emergency department (ED) visit who were tested for SARS-CoV-2 between March 10, 2020 and June 8, 2020 and had a positive test result by nucleic acid test (NAT) performed on a nasopharyngeal swab specimen. A total of 4968 patients met the study inclusion criteria, with a subsequent 23.1% (n = 1146/4968) all-cause mortality rate in the study cohort. To estimate overall risk by ABO type and account for the competing risks of in-hospital mortality and discharge, we calculated the cumulative incidence function (CIF) for each event. Cause-specific hazard ratios (csHRs) for in-hospital mortality and discharge were analyzed using multivariable Cox proportional hazards models | ||
| 520 | |a RESULTS: Type A blood was associated with the increased cause-specific hazard of death among COVID-19 patients compared to type O (HR = 1.17, 1.02-1.33, p = .02) and type B (HR = 1.32,1.10-1.58, p = .003) | ||
| 520 | |a CONCLUSIONS: Our study shows that ABO histo-blood group type is associated with the risk of in-hospital death in COVID-19 patients, warranting additional inquiry. Elucidating the mechanism behind this association may reveal insights into the susceptibility and/or immunity to SARS-CoV-2 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ABO | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a ABO Blood-Group System |2 NLM | |
| 700 | 1 | |a Mohrmann, Laurel |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Jamal |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Randin |e verfasserin |4 aut | |
| 700 | 1 | |a Chekuri, Sweta |e verfasserin |4 aut | |
| 700 | 1 | |a Assa, Andrei |e verfasserin |4 aut | |
| 700 | 1 | |a Spund, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes-Gil, Morayma |e verfasserin |4 aut | |
| 700 | 1 | |a Uehlinger, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Baron, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Paroder, Monika |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion |d 1961 |g 61(2021), 4 vom: 20. Apr., Seite 1064-1070 |w (DE-627)NLM00001107X |x 1537-2995 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2021 |g number:4 |g day:20 |g month:04 |g pages:1064-1070 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/trf.16339 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2021 |e 4 |b 20 |c 04 |h 1064-1070 | ||